Achievement and Safety of a Low Blood Pressure Goal in Chronic Renal Disease
J. Michael Lazarus(Fresenius (Germany)), Carol Stollar(National Institute of Diabetes and Digestive and Kidney Diseases), Andrew S. Levey(Tufts Medical Center), N. Carole Milas(National Institute of Diabetes and Digestive and Kidney Diseases), Lata Paranandi(National Institute of Diabetes and Digestive and Kidney Diseases), Vardaman M. Buckalew(University of Toledo Medical Center), Jacques J. Bourgoignie(National Institute of Diabetes and Digestive and Kidney Diseases), John C. Peterson(Moffitt Cancer Center), Jerome G. Porush(National Institute of Diabetes and Digestive and Kidney Diseases), J. Michael Soucie(National Institute of Diabetes and Digestive and Kidney Diseases), Sally Rauch(National Institute of Diabetes and Digestive and Kidney Diseases), Tom Greene(University Medical Center Groningen)
Cited by 227
Related Papers
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification
|Annals of Internal Medicine|2003|4.6k
Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)
|Kidney International|2005|3.9k
Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis
|Journal of the American Society of Nephrology|2004|2.7k